Caladrius Biosciences, Inc. (CLBS)
| Market Cap | 50.22M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -26.10M |
| Shares Out | 59.78M |
| EPS (ttm) | -0.58 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 523,260 |
| Open | 0.880 |
| Previous Close | 0.910 |
| Day's Range | 0.815 - 0.904 |
| 52-Week Range | 0.815 - 4.890 |
| Beta | 0.97 |
| Analysts | Buy |
| Price Target | 9.00 (+971.3%) |
| Earnings Date | Nov 4, 2021 |
About CLBS
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; OLOGO, a regenerative medicine advanced therapy for treating no-option refractory disabling angina; CLBS16 that is in Phase IIb clinical trial for the treatment of coronary microvascular dys...
Financial Performance
Financial StatementsAnalyst Forecast
According to 2 analysts, the average rating for CLBS stock is "Buy." The 12-month stock price forecast is 9.00, which is an increase of 971.30% from the latest price.
News
Caladrius Biosciences to Host Third Quarter 2021 Financial Results Conference Call on Thursday, November 4th at 4:30 ...
BASKING RIDGE, N.J., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
Caladrius Biosciences to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
BASKING RIDGE, N.J., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...
Caladrius Biosciences Announces Appointment of Kristen K. Buck, M.D.
BASKING RIDGE, N.J., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...
Caladrius Biosciences, Inc. (CLBS) Reports Q2 Loss, Misses Revenue Estimates
Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of 33.33% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st...
Caladrius Biosciences Reports Second Quarter 2021 Financial Results and Provides Business Update
Conference call begins today at 4:30 p.m. Eastern Time Conference call begins today at 4:30 p.m. Eastern Time
Caladrius Biosciences to Host Second Quarter 2021 Financial Results Conference Call on Thursday, August 5, 2021 at 4:...
BASKING RIDGE, N.J., July 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
Caladrius Biosciences to Present at Zooming with LD
BASKING RIDGE, N.J., July 22, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
Caladrius Bioscience To Start Testing Its CD34+ Cell Therapy in Diabetic Kidney Disease
The FDA has signed off Caladrius Bioscience Inc's (NASDAQ: CLBS) investigational new drug application for the study of CLBS201 for the treatment of diabetic kidney disease ("DKD"). The company plans to ...
Caladrius Biosciences to Assess its CLBS201 CD34+ Cell Therapy in Diabetic Kidney Disease
FDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function FDA authorizes new IND for the study of CLBS201 in patients with reduced kidney function
Caladrius Biosciences to Present at Noble Capital Markets Virtual Investor Forum during the 16th Annual World Stem Ce...
Presentation begins today at 10:30 a.m. Eastern time Presentation begins today at 10:30 a.m. Eastern time
A Trio of Net Current Asset Value Stock Picks
There are some investors who invest in U.S.-listed stocks that are trading below their liquidation values because they believe they can gain from these allocations after the market has reappraised the s...
Caladrius Biosciences Announces Participation in Upcoming Conferences in June 2021
BASKING RIDGE, N.J., June 01, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
New Strong Sell Stocks for May 27th
AFYA, BNL, CLBS, EKSO, and LLY have been added to the Zacks Rank #5 (Strong Sell) List on May 27, 2021
Caladrius Biosciences, Cassava Sciences Secure Non-Dilutive Funding For Product Development
Caladrius Biosciences Inc (NASDAQ: CLBS) has received $1.4 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program sponsored by the New Jer...
Caladrius Biosciences Receives $1.4 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certif...
BASKING RIDGE, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development o...
Caladrius Biosciences, Inc. (CLBS) Reports Q1 Loss, Lags Revenue Estimates
Caladrius Biosciences, Inc. (CLBS) delivered earnings and revenue surprises of -111.11% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the...
Caladrius Biosciences to Host First Quarter 2021 Financial Results Conference Call on Thursday, May 6, 2021 at 4:30 p...
BASKING RIDGE, N.J., April 29, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...
Is the Options Market Predicting a Spike in Caladrius Biosciences (CLBS) Stock?
Investors need to pay close attention to Caladrius Biosciences (CLBS) stock based on the movements in the options market lately.
Caladrius Biosciences, Inc. (CLBS) Upgraded to Buy: What Does It Mean for the Stock?
Caladrius Biosciences, Inc. (CLBS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Caladrius Biosciences to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
BASKING RIDGE, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development...
Caladrius Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update
Company demonstrates resilience despite COVID-19 challenges: Financial situation secure and development programs progressing
Caladrius Biosciences to Host Fourth Quarter and Full Year 2020 Financial Results Conference Call on Thursday, Februa...
BASKING RIDGE, N.J., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
Caladrius Biosciences, Inc. Closes $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
BASKING RIDGE, N.J., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
Caladrius Biosciences, Inc. Announces $65 Million Registered Direct Offerings Priced At-The-Market under Nasdaq Rules
BASKING RIDGE, N.J., Feb. 12, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...
Caladrius Biosciences Closes $25.0 Million Private Placement
BASKING RIDGE, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development ...